肺癌——美国癌症联合委员会第八版癌症分期手册的重大变化
第八版肺癌TNM分期基于国际肺癌研究协会数据库1999至2010年诊断的77,156例可评估患者分析修订。肿瘤大小分组细化,Tis和T1mi分别用于原位腺癌和微浸润腺癌;支气管内肿瘤距隆突<2 cm归为T2;全肺不张/肺炎归为T2;膈肌侵犯为T4;纵隔胸膜侵犯不再作为T描述符。N描述符不变但受累淋巴结站数有预后影响;M1b为单个胸外转移,M1c为单个器官或多个器官的多个胸外转移。IA期分为IA1-IA3,N1疾病除T3-T4N1M0为IIIA期外均为IIB期,新增IIIC期用于T3-T4N3M0,IV期分为IVA和IVB。
要点
- 肿瘤大小分组细化为T1a≤1 cm、T1b>1-2 cm、T1c>2-3 cm、T2a>3-4 cm、T2b>4-5 cm、T3>5-7 cm、T4>7 cm。
- 支气管内肿瘤距隆突<2 cm归为T2;全肺不张/肺炎归为T2;膈肌侵犯为T4;纵隔胸膜侵犯不再作为T描述符。
- N描述符不变但受累淋巴结站数有预后影响;M1b为单个胸外转移,M1c为单个器官或多个器官的多个胸外转移。
核心结论
- 该修订增强了预后判断能力,并将对肺癌患者的管理和未来研究产生重要影响。
研究设计与样本
- 基于国际肺癌研究协会数据库分析,纳入1999至2010年诊断的77,156例可评估肺癌患者。
主要发现
- 肿瘤大小分组:T1a≤1 cm;T1b>1至2 cm;T1c>2至3 cm;T2a>3至4 cm;T2b>4至5 cm;T3>5至7 cm;T4>7 cm。
- Tis和T1mi分别用于原位腺癌和微浸润腺癌。
- 支气管内肿瘤距隆突<2 cm预后优于其他T3描述符,归为T2;全肺不张/肺炎因具有T2预后归为T2;膈肌侵犯为T4;脏层胸膜侵犯不变,纵隔胸膜侵犯不再作为T描述符。
- N描述符不变,但受累淋巴结站数有预后影响;M1a不变,胸外转移分为单个胸外转移(新M1b)和单个器官或多个器官的多个胸外转移(M1c)。
- IA期分为IA1、IA2、IA3以对应T1a、T1b、T1cN0M0肿瘤;所有N1疾病除T3-T4N1M0为IIIA期外均为IIB期;新增IIIC期用于T3-T4N3M0;IV期分为IVA(M1a和M1b)和IVB(M1c)。
关键数值与推荐
- T1a:≤1 cm;T1b:>1至2 cm;T1c:>2至3 cm;T2a:>3至4 cm;T2b:>4至5 cm;T3:>5至7 cm;T4:>7 cm。
- Tis用于原位腺癌,T1mi用于微浸润腺癌。
- 支气管内肿瘤距隆突<2 cm归为T2;全肺不张/肺炎归为T2;膈肌侵犯为T4;纵隔胸膜侵犯不再作为T描述符。
- M1b为单个胸外转移,M1c为单个器官或多个器官的多个胸外转移。
- IA1对应T1aN0M0,IA2对应T1bN0M0,IA3对应T1cN0M0;N1疾病除T3-T4N1M0为IIIA期外均为IIB期;IIIC期用于T3-T4N3M0;IVA期包括M1a和M1b,IVB期包括M1c。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Answer questions and earn CME/CNE The revision for the eighth edition of the tumor, node, and metastasis (TNM) classification of lung cancer was based on analyses of the International Association for the Study of Lung Cancer database, which included 77,156 evaluable patients diagnosed with lung cancer from 1999 to 2010. Among tumor (T) descriptors, the following new tumor-size groups were created: T1a, ≤1 cm; T1b, >1 to 2 cm; T1c, >2 to 3 cm; T2a, >3 to 4 cm; T2b, >4 to 5 cm; T3, >5 to 7 cm; and T4, >7 cm. Tis and T1mi were introduced for adenocarcinoma in situ and minimally invasive adenocarcinoma, respectively. Endobronchial tumors located <2 cm from the carina have better prognosis than those with any other T3 descriptor and were classified as T2. Total atelectasis/pneumonitis was classified as a T2 descriptor, because it has a T2 prognosis. Diaphragmatic invasion is now T4. Visceral pleural invasion remains unchanged, and mediastinal pleura invasion, which is seldom used, disappears as a T descriptor. The lymph node (N) component descriptors are unchanged, but the number of involved nodal stations has prognostic impact. For the metastasis (M) component, M1a (intrathoracic metastases) remains unchanged, but extrathoracic metastases are divided into a single extrathoracic metastasis (new M1b) and multiple extrathoracic metastases in a single organ or multiple organs (M1c). Stage IA is now divided into IA1, IA2, and IA3 to accommodate T1a, T1b, and T1cN0M0 tumors, respectively; all N1 disease is stage IIB except for T3-T4N1M0 tumors, which are stage IIIA; a new stage IIIC is created for T3-T4N3M0 tumors; and stage IV is divided into IVA (M1a and M1b) and IVB (M1c). This revision enhances our capacity for prognostication and will have an important impact in the management of patients with lung cancer and in future research. CA Cancer J Clin 2017;67:138-155. © 2017 American Cancer Society.
引用
- Rami-Porta R, Asamura H, Travis WD, et al. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017. PMID: 28140453. doi:10.3322/caac.21390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。